ONC stock forecast, quote, news & analysis
BeOne Medicines Ltd is a holding company... Show more
BeOne Medicines (ONC) Stock Analysis: Pipeline Momentum Builds
Key Takeaways
- BeOne Medicines reported strong Q4 2025 revenue of $1.5 billion, up significantly year-over-year, driven by BRUKINSA sales exceeding $1.1 billion.
- Full-year 2025 revenue reached $5.343 billion, a 40% increase, with 2026 guidance set at $6.2–$6.4 billion.
- Analyst consensus remains bullish, with an average price target of $408, implying substantial upside from recent levels.
- Recent clinical advancements include orphan drug designation for a liver cancer asset and positive Phase 3 data for ZIIHERA.
- Stock has shown resilience in recent trading sessions amid broader biotech volatility, trading within its 52-week range of $196–$385.
- Wolfe Research initiated coverage with an Outperform rating, highlighting the company's oncology leadership.
Current Market Snapshot
BeOne Medicines (ONC) has navigated recent weeks with notable resilience in a volatile biotech sector. The stock has fluctuated within its established range, reflecting investor focus on robust commercial performance and pipeline catalysts. Key products like BRUKINSA continue to drive revenue growth, bolstering confidence amid macroeconomic pressures and sector rotations. Trading volumes have aligned with typical patterns, underscoring steady interest from institutional holders. Overall, ONC maintains a solid position, supported by strong fundamentals and positive analyst sentiment in the latest market cycle.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across diverse strategies. These bots employ varied approaches, including short-term signals, long-term holds, volatility plays, and sector-specific trends like energy, semiconductors, and infrastructure, with timeframes from hours to months. Among the 25 trending bots, performance highlights include annualized returns up to +164%, win rates from 53% to 86%, and profit factors reaching 11.45, showcasing their adaptability to current conditions. Only the most suitable for prevailing markets earn a spot here, helping traders identify high-potential opportunities. Explore these tools to enhance your strategy with data-driven insights.
Recent Developments Driving ONC Price Action
BeOne Medicines (ONC), a global oncology-focused biopharmaceutical company formerly known as BeiGene, has seen its stock influenced by a series of pivotal updates over recent weeks. The standout event was the release of Q4 and full-year 2025 financial results, which highlighted record growth. Q4 revenue hit $1.498 billion, a 33% year-over-year increase, propelled by global BRUKINSA (zanubrutinib, a BTK inhibitor (Bruton's Tyrosine Kinase inhibitor)) sales of $1.1 billion, up 38%. Full-year revenue reached $5.343 billion, up 40%, with non-GAAP diluted EPS of $8.09 per ADS (American Depositary Share). However, GAAP EPS of $0.58 missed elevated expectations, contributing to initial pressure despite the revenue beat.
Accompanying 2026 guidance called for revenue of $6.2–$6.4 billion and GAAP operating income of $700–$800 million, signaling a path to profitability but slightly below consensus revenue forecasts around $6.44 billion. This tempered enthusiasm, leading to some price consolidation as investors weighed execution risks against growth prospects.
On the clinical front, positive Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus chemotherapy—with or without TEVIMBRA (tislelizumab)—met dual primary endpoints of progression-free survival (PFS) in gastric cancer, boosting sentiment with strong survival signals. Additionally, the U.S. FDA granted Fast Track Designation to BGB-B2033, a bispecific antibody for hepatocellular carcinoma (HCC) post prior therapy, and orphan drug status for a liver cancer asset, underscoring pipeline potential in high-unmet-need areas.
Analyst activity intensified post-earnings. Wolfe Research initiated coverage on March 27 with an Outperform rating and $340 target, citing BRUKINSA's positioning and pipeline depth. Jefferies downgraded to Hold from Buy on March 16, cutting its target to $290 amid pipeline risks highlighted by an early-stage solid tumor trial termination. Barclays, Bernstein, Truist, RBC Capital, and Guggenheim maintained Buy ratings, with targets up to $425, reflecting optimism on 2026 milestones like sonrotoclax approvals and BGB-16673 data. Consensus leans Strong Buy, with an average target of $408.
These developments linked directly to price behavior: earnings drove an initial uptick on revenue strength, tempered by guidance and EPS miss; regulatory wins provided lifts; and mixed analyst notes fueled volatility. Institutional moves, like JPMorgan trimming shares, added short-term pressure, but overall sentiment shifted positively on oncology leadership. ONC's market cap stands at approximately $34 billion, with shares rebounding in recent sessions to around $297.
2026 Outlook and Key Factors to Monitor
As BeOne Medicines advances into 2026, investors should track several strategic elements shaping its trajectory. Revenue growth from BRUKINSA expansions in B-cell malignancies, alongside launches like sonrotoclax (BCL2 inhibitor) and potential approvals for BTK degraders, could solidify commercial momentum. Phase 3 readouts for zanidatamab combinations and BGB-16673 in chronic lymphocytic leukemia (CLL) represent critical catalysts, with 8–10 new molecular entities (NMEs) planned annually.
Opportunities lie in the "development superhighway" leveraging U.S., China, and global footprints for faster approvals and affordability. Free cash flow exceeding $350 million quarterly supports R&D, with over $4 billion in cash providing runway. Risks include pipeline setbacks, as seen in trial terminations, pricing pressures in oncology, and competition from established players. Regulatory progress on Fast Track assets like BGB-B2033 for HCC and macroeconomic factors affecting biotech funding will be pivotal. Balanced execution on profitability targets amid these dynamics positions BeOne for potential sector outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ONC's Stochastic Oscillator descending into oversold zone
The Stochastic Oscillator for ONC moved into oversold territory on May 18, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for ONC crossed bullishly above the 50-day moving average on May 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 229 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONC as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ONC turned negative on May 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
ONC moved below its 50-day moving average on May 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ONC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.390) is normal, around the industry mean (32.192). P/E Ratio (66.331) is within average values for comparable stocks, (49.929). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (323.173).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology